Information Provided By: 
Fly News Breaks for June 9, 2015
MNKD
Jun 9, 2015 | 09:31 EDT
Jefferies analyst Shaunak Deepak said feedback from 20 U.S. physicians at the American Diabetes Association meeting regarding MannKind's Afrezza was "largely positive." Deepak notes that while only six of the physicians had written Afrezza prescriptions to date, only one of the physicians objected to potentially prescribing the drug. The analyst says the results are "marginally better" than the 8%-12% non-prescriber rate predicted by the firm's recent survey. Deepak keeps a Buy rating on MannKind shares with a $9 price target.
News For MNKD From the Last 2 Days
There are no results for your query MNKD
